DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* CYTHERIS *


 

1999 - IDF
Issy-les-Moulineaux
(near Paris)
www.cytheris.com

 

Discovery, Immunology
Key words: Immune modulation, Cancer, HIV, HCV, Recombinant interleukin
Mission: to discover and develop new therapies for immune modulation, by reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT)
Clients: Prescribers
info@cytheris.com

Age: 18 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Marron (Damian) [born 1962, Pharmacologist, ex-3M Pharma, Orphan Europe, Rhône Poulenc Rorer, Glaxo, Nicox, Trophos]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Vannier (Bertrand)
BusDev: Keatinge (Richard W.) [ex-BioAlliance Pharma]
Financers (Hist.): Bioam, GestionT2C2/Bio, CDP Capital Technology Ventures, AXA P.E., Crédit Agricole P.E., CDC Innovation, Forbion, Caisse de dépôt et placement du Québec (Canada) (registered capital 2006 = 52.5 M€)

Turnover (M€) : 0.01 (2009), 0.09 (2007), 0.14 (2006)
Total funding (M€) : 43.3
Last funding (M€) : 12.0
Focus : Cancers
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .07 Registration : orphan Drug designation by EMA for CYT107 in the treatment of Progressive Multifocal Leucoencephalopathy (PML) MKTG [13 years]
2012 .06 Nomination : Damian Marron, as CEO (Michel Morre on leave) ORGN [13 years]
2011 .06 Partnering development project with ImmunID and Centre Léon Bérard (Lyon), named DivRescue for cancer management R&D [12 years]
2011 .05 Clinical trial (phase II) for recombinant IL-7 combined with Xeloda in treatment of metastatic breast cancer (beginning) CLIN [12 years]
2010 .11 Clinical trial (phase II) for recombinant IL-7 combined with anti-retrovirals Raltegravir and Maraviroc to attack the viral reservoir in HIV patients (beginning) CLIN [11 years]
2010 .07 3rd round-financing : 12.0 M€, by CDC Entreprises (on behalf of FSI), along with historical investors RFINC [11 years]
2010 .02 Patent : granted from U.S. office covering the preparation and uses of its Glycosylated Recombinant Human Interleukin-7 (CYT107) LEGAL [11 years]
2009 .06 Research : publication in Nature Medicine showing that combination of Interleukin-7 with viral vaccine boosts immunity to tumors R&D [10 years]
2009 .03 Clinical trial (phase IIa) for recombinant IL-7 (completed), which induces a dramatic and prolonged CD4 and CD8 T cell expansion, sustained for 48 weeks in HIV patients CLIN [10 years]
2008 .07 Financing (no interest loan) : 1.5 M€, by OSEO, to support its ongoing clinical development program in hepatitis C (HCV) DEBT [9 years]
2007 .02 Clinical trial (phase I) for recombinant IL-7 (beginning) CLIN [8 years]
2006 .10 2nd round-financing : 24.3 M€, by CDC Innovation with ABN AMRO Capital Life Sciences (today, Forbion) and previous shareholders RFINB [7 years]
2005 .05 Licensing-in of a new immuno-modulating agent for HIV from New York University LICIN [6 years]
2003 .00 Set-up of US subsidiary in Rockville, Maryland ORGC [3 years]
2002 .07 1st round-financing : 7.0 M€, by Bioam with two Canadian funds, GestionT2C2/Bio and CDP Capital Technology Ventures, plus AXA P.E. and Crédit Agricole P.E. RFINA [3 years]
1999 .04 Licensing-in of Interleukin-7 (IL-7) from Sanofi-Aventis LICIN [0 year]
1999 .01 Company founded by Michel Morre (CEO), as Biotech Inflection Point ORGF [0 year]

Actualisation / Updating: 18-Jun-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende